U.S. markets open in 2 hours 22 minutes
  • S&P Futures

    3,888.25
    -10.50 (-0.27%)
     
  • Dow Futures

    31,463.00
    -46.00 (-0.15%)
     
  • Nasdaq Futures

    13,231.50
    -48.25 (-0.36%)
     
  • Russell 2000 Futures

    2,260.70
    -14.10 (-0.62%)
     
  • Crude Oil

    60.70
    +0.06 (+0.10%)
     
  • Gold

    1,726.10
    +3.10 (+0.18%)
     
  • Silver

    26.35
    -0.33 (-1.23%)
     
  • EUR/USD

    1.2032
    -0.0028 (-0.23%)
     
  • 10-Yr Bond

    1.4460
    0.0000 (0.00%)
     
  • Vix

    23.34
    -4.61 (-16.49%)
     
  • GBP/USD

    1.3924
    +0.0003 (+0.03%)
     
  • USD/JPY

    106.9260
    +0.1960 (+0.18%)
     
  • BTC-USD

    48,984.80
    +1,388.04 (+2.92%)
     
  • CMC Crypto 200

    986.35
    -0.30 (-0.03%)
     
  • FTSE 100

    6,628.93
    +40.40 (+0.61%)
     
  • Nikkei 225

    29,408.17
    -255.33 (-0.86%)
     

TherapeuticsMD Earnings Preview

  • Oops!
    Something went wrong.
    Please try again later.
Benzinga Insights
·2 min read
  • Oops!
    Something went wrong.
    Please try again later.

On Tuesday, March 02, TherapeuticsMD (NASDAQ:TXMD) will report its last quarter's earnings. Here is Benzinga's preview of the company's release.

What Are Earnings, Net Income, And Earnings Per Share?

Earnings and especially earnings per share (EPS) are useful measures of a company's profitability. Total earnings, which is also referred to as net income, equals total revenue minus total expenses. EPS equals to net income divided by the number of shares outstanding.

Earnings And Revenue

Based on management's projections, TherapeuticsMD analysts modeled for a loss of $0.1 per share on sales of $21.89 million. In the same quarter last year, TherapeuticsMD announced EPS of $0.19 on revenue of $15.90 million.

What Are Analyst Estimates And Earnings Surprises, And Why Do They Matter?

Wall Street analysts who study this company will publish analyst estimates of revenue and EPS. The averages of all analyst EPS and revenue estimates are called the "consensus estimates"; these consensus estimates can have a significant effect on a company's performance during an earnings release. When a company posts earnings or revenue above or below a consensus estimate, it has posted an "earnings surprise", which can really move a stock depending on the difference between actual and estimated values.

View more earnings on TXMD

If the company were to post earnings in line with the consensus estimate when it reports Tuesday, EPS would be up 47.37%. Sales would be up 37.66% on a year-over-year basis. TherapeuticsMD's reported EPS has stacked up against analyst estimates in the past like this:

EPS Estimate

-0.14

-0.17

-0.19

-0.19

EPS Actual

-0.12

-0.19

-0.21

-0.19

Revenue Estimate

15.33 M

10.20 M

11.30 M

12.83 M

Revenue Actual

19.34 M

10.70 M

12.25 M

15.90 M

Stock Performance

Shares of TherapeuticsMD were trading at $1.52 as of February 26. Over the last 52-week period, shares are down 4.29%. Given that these returns are generally negative, long-term shareholders are likely unhappy going into this earnings release.

Do not be surprised to see the stock move on comments made during its conference call. TherapeuticsMD is scheduled to hold the call at 08:30:00 ET and can be accessed here.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.